29
Views
11
CrossRef citations to date
0
Altmetric
CaseReport Article

Molecular Remission Following High-Dose Hydroxyurea and Fludarabine Plus Cytarabine in a Patient with Simultaneous Acute Myeloid Leukemia and Low-Grade Lymphoma

, , , , , , , , & show all
Pages 671-674 | Published online: 01 Jul 2009

References

  • Roberts P. D., Foster P. M. Chronic lymphocyte leukemia associated with acute myelomonocytic leukemia. Br J Haematol 1973; 25: 203–206
  • Hamilton P. J. Concomitant myeloblastic and lymphocytic leukemia. Lancet 1976; 1: 373
  • Wamick R., Glodstone A. H., Janossy G. Chronic lymphocytic leukaemia uncovered by successful treatment of acute myeloid leukaemia. Br J Haematol 1976; 2: 1111–1112
  • Lawlor E., Mc Cann S. K., Welan A., Greally J., Temperley IJ. Acute myeloid leukaemia occurring in untreated chronic lymphatic leukaemia. Br J Haematol 1979; 43: 369–373
  • Manoharam A., Catovsky D., Clein P., Traub M. E., Castello C., O'Brien M., Boralessa H., Galton D. A.G. Simulteneous or spontaneous occurrence of lympho and myeloproliferative disorders: a report of four cases. Br J Haematol 1981; 48: 111–116
  • Maureen G., Conlan M. G., Mosher D. F. Concomitant chronic lymphocytic leukemia, acute myeloid leukemia and thrombosis with protein C deficiency. Case report and review of the literature. Cancer 1989; 63: 1398–1401
  • Caballero M. D., Gonzales M., Canizo M. C., Orfao A., Nieto M. J., San Miguel J. F. Concomitant chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Complete remission of CLL achieved with high dose cytosine arabinoside. Leukemia 1992; 6: 856–858
  • Lima M., Porto B., Rodrigues M., Dos Anjos, Teixeira M., Coutinho J., Ribeiro A. C.P., Malheiro M. I., Justica B. Cytogenetic findings in a patient presenting simultaneously with chronic lymphocytic leukemia and acute myeloid leukemia. Cancer Genet Cytogenet 1996; 87: 38–40
  • Gòmez-Arbonés J., Gallart M. A., Mellado A., Marco V., Panadés M.J., Macié J.M. Concomitant diagnosis of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). Importance of flow cytometry in the diagnosis of CLL without lymphocytosis accompanying AML. Eur J Haematol 1997; 59: 335–337
  • Mateu R., Bellido M., Sureda A., Gonzalez Y., Rubiol E., Aventin A., Nomdedeu J. Concomitant chronic lymphocytic leukemia and acute myeloid leukemia with an uncommon immunophenotype. Am J Hematol 1997; 56: 281–287
  • Kapadia S. B., Kaplan S. S. Simultaneous occurrence of non-Hodgkin's lymphoma and acute myelomonocytic leukemia. Cancer 1979; 44: 2316–23
  • Kjelsberg C. R., Nathwani B. N., Rappaport H. Acute myeloblastic leukemia developing in patients with mediastinal lymphoblastic lymphoma. Cancer 1979; 44: 2316–23
  • Jaalouk G., Avvisati G., Latagliata R., Paccbiarotti A., Pulsoni A., Mecarocci S., Malagnino F. Simultaneous occurrence of large B-cell non-Hodgkin's lymphoma and myelodysplastic syndrome rapidly evolving into acute myeloblastic leukemia. Leuk Lymphoma 1996; 21: 339–341
  • Petti M. C., Aloe Spiriti M. A., Montefiisco E., Redi R., Mancini M., Comandini A., D'Elia G. M., Mandelli F. High-dose hydroxyurea (HIGH-HY) in the treatment of poor risk acute myeloid leukemia. Br J Haematol 1998; 102((1))222
  • Estey E., Tholl P., Andreeff M., Beran M., Kantarjian H., O'Brien S., Escudier S., Robertson L. E., Roller C., Komblau S., Pierce S., Freireich E. J., Deisseroth A., Keating M. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromesxomparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671–678
  • Byrd J. C., Rai K. R., Sausville E. A., Grever M. R. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol 1998; 25: 1–11
  • Tafuri A., de Felice L., Petrucci M. T., Mascolo M. G., Ricciardi M. R., Ciliberti C., Martelli M. P., Petti M. C. Multidrug Resistance expression and proliferative studies in poor risk AML treated with the FLAG regimen. Cytokines and Molecular Therapy 1995; 1: 301–307

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.